Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma

Next Previous
Trial Profile

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Epcoritamab (Primary) ; Ibrutinib (Primary) ; Lenalidomide (Primary) ; Polatuzumab vedotin (Primary) ; Prednisolone (Primary) ; Prednisone (Primary) ; Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Acronyms EPCORE NHL-5
  • Sponsors AbbVie

Most Recent Events

  • 05 Jun 2025 Planned number of patients changed from 622 to 565.
  • 14 May 2025 According to Genmab media release, data from this study will be presented at the 30th European Hematology Association (EHA) Congress, being held in Milan, Italy, and virtually, June 12-15, 2025.
  • 07 Jan 2025 Planned End Date changed from 1 Jun 2031 to 1 Nov 2032.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top